{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:11:49Z","timestamp":1793362309329,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.msard.2021.102781","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T11:49:38Z","timestamp":1611143378000},"page":"102781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3193-8726","authenticated-orcid":false,"given":"Riccardo","family":"Garbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Lorenzut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6737-2779","authenticated-orcid":false,"given":"Ilaria","family":"Del Negro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6525-9529","authenticated-orcid":false,"given":"Giovanni","family":"Merlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3526-1414","authenticated-orcid":false,"given":"Gian Luigi","family":"Gigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cargnelutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.102781_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2018.00005","article-title":"Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis","volume":"9","author":"Mills","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2021.102781_bib0002","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1212\/NXI.0000000000000076","article-title":"Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate","volume":"2","author":"Spencer","year":"2015","journal-title":"Neurol. Neuroimmunol. NeuroInflamm."},{"key":"10.1016\/j.msard.2021.102781_bib0003","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1212\/WNL.0000000000007262","article-title":"Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice","volume":"92","author":"Mehta","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102781_bib0004","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","article-title":"Characterizing absolute lymphocyte count profiles in dimethyl fumarate'treated patients with MS Patient management considerations","volume":"6","author":"Fox","year":"2016","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.msard.2021.102781_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jns.2019.01.007","article-title":"Factors associated with dimethyl fumarate-induced lymphopenia","volume":"398","author":"Sainz de la Maza","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2021.102781_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0228617","article-title":"Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients","volume":"15","author":"Goldman","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2021.102781_bib0007","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1177\/1352458517703799","article-title":"Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS","volume":"24","author":"Fleischer","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.102781_bib0008","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00415-019-09557-w","article-title":"Risk factors for lymphopenia in patients with relapsing\u2013remitting multiple sclerosis treated with dimethyl fumarate","volume":"267","author":"Morales","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.102781_bib0009","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40263-020-00714-8","article-title":"Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not associated with short-term treatment response and risk of infections in a real-life MS population","volume":"34","author":"Boffa","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2021.102781_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101871","article-title":"Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study","volume":"38","author":"Lanzillo","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102781_bib0011","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1177\/1352458514559299","article-title":"Dimethyl fumarate associated lymphopenia in clinical practice","volume":"21","author":"Longbrake","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.102781_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000397","article-title":"Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation","volume":"4","author":"Wright","year":"2017","journal-title":"Neurol. Neuroimmunol. NeuroInflamm."},{"key":"10.1016\/j.msard.2021.102781_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2019.01343","article-title":"Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort","volume":"10","author":"Manni","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2021.102781_bib0014","article-title":"Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance","volume":"1","author":"Longbrake","year":"2015","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2021.102781_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002685","article-title":"Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study","volume":"15","author":"Warny","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.msard.2021.102781_bib0016","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00415-017-8509-9","article-title":"Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases","volume":"264","author":"Gieselbach","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.102781_bib0017","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.msard.2018.09.009","article-title":"Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient","volume":"26","author":"Perini","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102781_bib0018","first-page":"e203","article-title":"Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate","volume":"3","author":"Ma","year":"2016","journal-title":"Neurology: Neuroimmunol. NeuroInflamm."},{"key":"10.1016\/j.msard.2021.102781_bib0019","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1177\/1352458517741207","article-title":"Diffuse dermatophytosis occurring on dimethyl fumarate therapy","volume":"24","author":"Greenstein","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.102781_bib0020","unstructured":"European Medicines Agency. Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera Related recommendations apply to other fumarate medicines. 2015; 44: 1\u20134."},{"key":"10.1016\/j.msard.2021.102781_bib0021","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2021.102781_bib0022","article-title":"Common Terminology Criteria for Adverse Events (CTCAE).v.5.0","volume":"155","year":"2017","journal-title":"Cancer Ther. Eval. Progr."},{"key":"10.1016\/j.msard.2021.102781_bib0023","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.msard.2017.12.003","article-title":"Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count","volume":"20","author":"Baharnoori","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102781_bib0024","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.arr.2017.10.005","article-title":"The influence and impact of ageing and immunosenescence (ISC) on adaptive immunity during multiple sclerosis (MS) and the animal counterpart experimental autoimmune encephalomyelitis (EAE)","volume":"41","author":"Bolton","year":"2018","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.msard.2021.102781_bib0025","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419843450","article-title":"Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age","volume":"12","author":"Briner","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.102781_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2019.01039","article-title":"Genetic study of severe prolonged lymphopenia in multiple sclerosis patients treated with dimethyl fumarate","volume":"10","author":"Sangurdekar","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.msard.2021.102781_bib0027","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ane.12882","article-title":"Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation","volume":"137","author":"Zecca","year":"2018","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1016\/j.msard.2021.102781_bib0028","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40263-018-0543-3","article-title":"Safety and efficacy of dimethyl fumarate in multiple sclerosis: an italian, multicenter, real-world study","volume":"32","author":"Mirabella","year":"2018","journal-title":"CNS Drugs"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482100047X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482100047X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:56:54Z","timestamp":1761901014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482100047X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":28,"alternative-id":["S221103482100047X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102781","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102781"}}